| abstract |
The objective invention provides R (+) - N-methylpropargyl-aminoindan or a pharmaceutically acceptable salt thereof, and a composition containing R (+) - N-propargyl1 (R) -aminoindane or a pharmaceutically acceptable salt thereof, and a compound of R (+) - N-methyl-propargyl aminoindane or a salt thereof. Methods of validation of a batch of rasagiline for use in a pharmaceutical formulation and a method of validation of a formulation of rasagiline for distribution are also described, based on the content of R (+) - N-methyl-propargyl aminoindane or a Get out of it. |